SCHEDULE 13G/A: BlackRock Amends Stake in PROKIDNEY CORP, Holding 1.4% of Class A Stock

BlackRock, Inc. has filed an amended Schedule 13G, disclosing a beneficial ownership of 1.4% of PROKIDNEY CORP's Class A Stock as of June 30, 2025.

Summary

• BlackRock, Inc. reported beneficial ownership of 1,764,602 shares of PROKIDNEY CORP's Class A Stock.
• This aggregate amount represents 1.4% of the total Class A Stock outstanding.
• BlackRock holds sole voting power over 1,756,859 shares and sole dispositive power over 1,764,602 shares.
• The filing is an Amendment No. 1 to a Schedule 13G, indicating a change from a previous filing.
• The filing date is July 17, 2025, and the event date requiring the filing is June 30, 2025.
• BlackRock, Inc. is a Delaware corporation and filed as a parent holding company or control person.
• No single subsidiary of BlackRock beneficially owns 5% or greater of the outstanding shares of PROKIDNEY CORP.

Sentiment

Score: 5

Explanation: The document is a standard beneficial ownership disclosure, which is neutral in sentiment. It simply reports a factual ownership stake without indicating positive or negative performance or outlook.

Positives

• BlackRock, a major institutional investor, holds a stake in PROKIDNEY CORP, which can be viewed as a vote of confidence in the company's long-term prospects.
• The filing indicates that the securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.

Negatives

• The reported beneficial ownership of 1.4% is a relatively small stake, indicating limited direct influence or significant investment concentration by BlackRock.

Risks

• The document itself does not detail specific risks related to PROKIDNEY CORP's operations or financial health, as it is a beneficial ownership disclosure.

Future Outlook

This Schedule 13G filing does not contain any forward-looking statements or guidance regarding PROKIDNEY CORP's future performance or BlackRock's investment strategy beyond the certification that the shares are held in the ordinary course of business.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."

Industry Context

This filing is a routine disclosure of institutional ownership, common in the financial industry. It reflects BlackRock's passive investment in PROKIDNEY CORP, a company in the biotechnology or pharmaceutical sector, without providing specific insights into broader industry trends or competitive positioning.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional investor's stake, which can influence investor confidence and perception of the stock.
• Investment Professionals: Offers data points for tracking institutional ownership and potential shifts in large fund holdings.

Key Dates

Keywords

BlackRock, PROKIDNEY CORP, Schedule 13G, Beneficial Ownership, Class A Stock, SEC Filing, Institutional Investor, Equity Stake